JP2019112389A5 - - Google Patents

Download PDF

Info

Publication number
JP2019112389A5
JP2019112389A5 JP2018192916A JP2018192916A JP2019112389A5 JP 2019112389 A5 JP2019112389 A5 JP 2019112389A5 JP 2018192916 A JP2018192916 A JP 2018192916A JP 2018192916 A JP2018192916 A JP 2018192916A JP 2019112389 A5 JP2019112389 A5 JP 2019112389A5
Authority
JP
Japan
Prior art keywords
composition according
composition
alkyl
hydrogen
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018192916A
Other languages
Japanese (ja)
Other versions
JP2019112389A (en
JP7373824B2 (en
Filing date
Publication date
Application filed filed Critical
Publication of JP2019112389A publication Critical patent/JP2019112389A/en
Publication of JP2019112389A5 publication Critical patent/JP2019112389A5/ja
Priority to JP2023115450A priority Critical patent/JP2023134664A/en
Application granted granted Critical
Publication of JP7373824B2 publication Critical patent/JP7373824B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (13)

以下の構造
Figure 2019112389
 を持つ化合物、又はその薬学的に許容可能な塩、代謝産物、溶媒和物、或いはプロドラッグ、及び１つ以上の抗癌剤を含む、被験体の膵臓癌を処置するのに使用するための組成物であって；
式中、
ＸとＹの各々は独立して、酸素又は硫黄であり；
Ｒは、水素又はＣ（＝Ｏ）Ｃ１−Ｃ８アルキルであり；
Ｒ１、Ｒ２、及びＲ３の各々は独立して、水素、メチル、又は（ＣＨ２）ｍ−ＣＨ３であり、ｍ＝１−１２であり；
Ｒ４は、Ｈ、Ｃ１−Ｃ８アルキル、Ｃ２−Ｃ８アルケニル、Ｃ２−Ｃ８アルキニル、或いは、Ｃ１−Ｃ８アルキル、Ｃ２−Ｃ８アルケニル、Ｃ２−Ｃ８アルキニル、Ｃ３−Ｃ８シクロアルキル、及びＣ１−Ｃ８ハロアルキルから選択された１つ以上の置換基で随意に置換したアリールであり；
ｎ＝１−１２であり、
１つ以上の抗癌剤は、エルロチニブ、５−ＦＵ、オキサリプラチン、イリノテカン、ゲムシタビン、パクリタキセル、またはそれらの組み合わせである
ことを特徴とする組成物。 The following structure
Figure 2019112389
 A composition for use in treating a subject's pancreatic cancer, comprising a compound with, or a pharmaceutically acceptable salt, metabolite, solvate, or prodrug thereof, and one or more anticancer agents. And;
During the ceremony
Each of X and Y is independently oxygen or sulfur;
R is hydrogen or C (= O) C 1- C 8 alkyl;
Each of R 1 , R 2 , and R 3 is independently hydrogen, methyl, or (CH 2 ) m- CH 3 , and m = 1-12 ;
R 4 is, H, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, or, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, An aryl optionally substituted with one or more substituents selected from C 3- C 8 cycloalkyl and C 1- C 8 haloalkyl;
n = 1-12 der is,
One or more anti-cancer agents are compositions characterized by being erlotinib, 5-FU, oxaliplatin, irinotecan, gemcitabine, paclitaxel, or a combination thereof. １つ以上の抗癌剤は、ゲムシタビン、パクリタキセル、又はそれらの組み合わせである、ことを特徴とする請求項１に記載の組成物。 One or more anticancer agents, gemcitabine, paclitaxel, or a combination thereof, that the composition according to claim 1, wherein the. 免疫療法剤を更に含む、請求項１に記載の組成物。 The composition according to claim 1, further comprising an immunotherapeutic agent. Ｒは、水素、Ｃ（＝Ｏ）Ｃ R is hydrogen, C (= O) C ３3 ＨH ８8 、Ｃ（＝Ｏ）Ｃ, C (= O) C ２2 ＨH ５5 、又はＣ（＝Ｏ）ＣＨ, Or C (= O) CH ３3 である、ことを特徴とする請求項１乃至３の何れか１つに記載の組成物。The composition according to any one of claims 1 to 3, wherein the composition is the same. Ｒ R １1 、Ｒ, R ２2 、及びＲ, And R ３3 の各々は独立して、水素、メチル、エチル、プロピル、ブチル、ペンチル、ヘキシル、ヘプチル、又はオクチルである、ことを特徴とする請求項１乃至４の何れか１つに記載の組成物。The composition according to any one of claims 1 to 4, wherein each of the above is independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl. 前記化合物は The compound is
Figure 2019112389
Figure 2019112389
 である、ことを特徴とする請求項１乃至５の何れか１つに記載の組成物。The composition according to any one of claims 1 to 5, wherein the composition is the same. 自身の膵臓癌が、ゲムシタビン、パクリタキセル、又はそれらの組み合わせに対して抵抗性があり、難治性であり、或いは反応しない患者の処置に使用するための、以下の構造 The following structures for use in the treatment of patients whose pancreatic cancer is resistant, refractory, or unresponsive to gemcitabine, paclitaxel, or a combination thereof:
Figure 2019112389
Figure 2019112389
 を持つ治療上有効な量の化合物、又はその薬学的に許容可能な塩、代謝産物、溶媒和物、或いはプロドラッグを含む、医薬組成物であって、A pharmaceutical composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, metabolite, solvate, or prodrug thereof.
式中、During the ceremony
ＸとＹの各々は独立して、酸素又は硫黄であり； Each of X and Y is independently oxygen or sulfur;
Ｒは、水素又はＣ（＝Ｏ）Ｃ R is hydrogen or C (= O) C １1 −Ｃ-C ８8 アルキルであり；Alkyl;
Ｒ R １1 、Ｒ, R ２2 、及びＲ, And R ３3 の各々は独立して、水素、メチル、又は（ＣＨEach of them is independent of hydrogen, methyl, or (CH). ２2 ）) ｍm −ＣＨ-CH ３3 であり；And;
Ｒ R ４4 は、Ｈ、ＣH, C １1 −Ｃ-C ８8 アルキル、ＣAlkyl, C ２2 −Ｃ-C ８8 アルケニル、ＣAlkenyl, C ２2 −Ｃ-C ８8 アルキニル、或いは、ＣAlkyne or C １1 −Ｃ-C ８8 アルキル、ＣAlkyl, C ２2 −Ｃ-C ８8 アルケニル、ＣAlkenyl, C ２2 −Ｃ-C ８8 アルキニル、ＣAlkyne, C ３3 −Ｃ-C ８8 シクロアルキル、及びＣCycloalkyl and C １1 −Ｃ-C ８8 ハロアルキルから選択された１つ以上の置換基で随意に置換したアリールであり；Aryl optionally substituted with one or more substituents selected from haloalkyl;
ｎ＝１−１２である n = 1-12
ことを特徴とする医薬組成物。A pharmaceutical composition characterized by that. 前記化合物、又はその薬学的に許容可能な塩、代謝産物、溶媒和物、或いはプロドラッグは、経口、非経口、静脈内、又は注入によって投与される、ことを特徴とする請求項１又は７に記載の組成物。 Claim 1 or 7 characterized in that the compound, or a pharmaceutically acceptable salt, metabolite, solvate, or prodrug thereof, is administered orally, parenterally, intravenously, or by infusion. The composition according to. 免疫療法剤を更に含む、請求項１又は７に記載の組成物。 The composition according to claim 1 or 7, further comprising an immunotherapeutic agent. Ｒは、水素、Ｃ（＝Ｏ）Ｃ R is hydrogen, C (= O) C ３3 ＨH ８8 、Ｃ（＝Ｏ）Ｃ, C (= O) C ２2 ＨH ５5 、又はＣ（＝Ｏ）ＣＨ, Or C (= O) CH ３3 である、ことを特徴とする請求項１又は７に記載の組成物。The composition according to claim 1 or 7, wherein the composition is the same. Ｒ R １1 、Ｒ, R ２2 、及びＲ, And R ３3 の各々は独立して、水素、メチル、エチル、プロピル、ブチル、ペンチル、ヘキシル、ヘプチル、又はオクチルである、ことを特徴とする請求項１又は７に記載の組成物。The composition according to claim 1 or 7, wherein each of the above is independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl. Ｒ R ４4 は、Ｈ、又は、ＣIs H or C １1 −Ｃ-C ８8 アルキル、ＣAlkyl, C ２2 −Ｃ-C ８8 アルケニル、ＣAlkenyl, C ２2 −Ｃ-C ８8 アルキニル、ＣAlkyne, C ３3 −Ｃ-C ８8 シクロアルキル、又はＣCycloalkyl, or C １1 −Ｃ-C ８8 ハロアルキルから選択された１つ以上の置換基で随意に置換したＣC optionally substituted with one or more substituents selected from haloalkyl １1 −Ｃ-C ８8 アルキルである、ことを特徴とする請求項１又は７に記載の組成物。The composition according to claim 1 or 7, wherein the composition is alkyl. 前記化合物は The compound is
Figure 2019112389
Figure 2019112389
 である、ことを特徴とする請求項１又は７に記載の組成物。The composition according to claim 1 or 7, wherein the composition is the same.
JP2018192916A 2017-12-20 2018-10-11 Therapeutic composition for treating pancreatic cancer Active JP7373824B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023115450A JP2023134664A (en) 2017-12-20 2023-07-13 Therapeutic compositions for treating pancreatic cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762608549P 2017-12-20 2017-12-20
US62/608,549 2017-12-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023115450A Division JP2023134664A (en) 2017-12-20 2023-07-13 Therapeutic compositions for treating pancreatic cancer

Publications (3)

Publication Number Publication Date
JP2019112389A JP2019112389A (en) 2019-07-11
JP2019112389A5 true JP2019112389A5 (en) 2021-11-18
JP7373824B2 JP7373824B2 (en) 2023-11-06

Family

ID=66948249

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018192916A Active JP7373824B2 (en) 2017-12-20 2018-10-11 Therapeutic composition for treating pancreatic cancer
JP2023115450A Pending JP2023134664A (en) 2017-12-20 2023-07-13 Therapeutic compositions for treating pancreatic cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023115450A Pending JP2023134664A (en) 2017-12-20 2023-07-13 Therapeutic compositions for treating pancreatic cancer

Country Status (4)

Country Link
JP (2) JP7373824B2 (en)
KR (1) KR102620231B1 (en)
AU (1) AU2018247249B2 (en)
CA (1) CA3020933C (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101343247B (en) * 2007-07-12 2011-01-19 国鼎生物科技股份有限公司 Cyclohexenone extract of antrodia camphorata
TW201102075A (en) * 2009-07-09 2011-01-16 Golden Biotechnology Corp Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of pancreatic cancer
CN102000046B (en) * 2009-09-02 2012-05-30 国鼎生物科技股份有限公司 Application of antrodia camphorata cyclohexenone compound in preparing medicine for inhibiting growth of pancreatic cancer tumor cells
TWI612026B (en) 2013-02-20 2018-01-21 國鼎生物科技股份有限公司 Cyclohexenone compositions and process for making thereof
US20150018296A1 (en) * 2013-03-15 2015-01-15 Golden Biotechnology Corporation Therapeutic methods and compositions utilizing cyclohexenone compounds

Similar Documents

Publication Publication Date Title
JP2018530549A5 (en)
JP2013532652A5 (en)
JP2014531434A5 (en)
RU2008136188A (en) ANTI-CANCER PHARMACEUTICAL COMPOSITION
JP2019055988A5 (en) Therapeutic compounds and pharmaceutical compositions
JP2016503414A5 (en)
JP2014509647A5 (en)
JP2010514797A5 (en)
JP2015508103A5 (en)
JP2018504437A5 (en)
JP2014504256A5 (en)
JP2016521273A5 (en)
JP2019524883A5 (en)
DE10178132T1 (en) Antiviral agent
JP2014193925A5 (en)
JP2012519691A5 (en)
JP2016531871A5 (en)
RU2007116987A (en) NEW COMPOUNDS
JP2017501237A5 (en)
JP2019500387A5 (en)
JP2019507111A5 (en)
JP2016501838A5 (en)
JP2019507114A5 (en)
JP2017505785A5 (en)
JP2017537937A5 (en)